ArticleJCO precision oncology2021
Implementation of a Molecular Tumor Registry to Support the Adoption of Precision Oncology Within an Academic Medical Center: The Duke University Experience.
Article in JCO precision oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- The usage of population and disease registries as pre-screening tools for clinical trials, a systematic review.Systematic reviews · 2024Pooled it
- Precision cancer medicine in Europe: a mixed-methods study on infrastructure for extended molecular diagnostics.Journal of cancer research and clinical oncology · 2026Article
- Utility of Germline, Somatic and ctDNA Testing in Adults With Cancer.Cancer medicine · 2025Review
- Revolutionizing Cancer Registries: The Promise and Challenges of Integrating Molecular Markers for Enhanced Patient Care and Research.Journal of registry management · 2025Article
- Expansion of an Academic Molecular Tumor Board to Enhance Access to Biomarker-Driven Trials and Therapies in the Rural Southeastern United States.Current oncology (Toronto, Ont.) · 2024Article
- Association of Race and Ethnicity with Genomic Testing at a Comprehensive Cancer Center in North Carolina.Cancer research communications · 2024Article
- Comprehensive Genomic Profiling in Non-Myeloid Hematologic Malignancies Identifies Variants That Can Alter Clinical Practice.Hematology reports · 2024Article
- Clinical bioinformatics desiderata for molecular tumor boards.Briefings in bioinformatics · 2024Review
- Clinical genetics in breast cancer.Journal of surgical oncology · 2024Review
- Effects of Ataxia-Telangiectasia Mutated Variants on Radionecrosis and Local Control After Stereotactic Radiation Surgery for Non-Small Cell Lung Cancer Brain Metastases.Advances in radiation oncology · 2024Article
- Impact ofJournal of radiosurgery and SBRT · 2024Article
- Identification of an optimal mutant allele frequency to detect activatingJournal of gastrointestinal oncology · 2023Article
- The Molecular Tumor Board of the Regina Elena National Cancer Institute: from accrual to treatment in real-world.Journal of translational medicine · 2023Article
- The Cooperative Human Tissue Network of the National Cancer Institute: Supporting Cancer Research for 35 Years.Molecular cancer therapeutics · 2023Article
- Concordance Between Genomic Alterations Detected by Tumor and Germline Sequencing: Results from a Tertiary Care Academic Center Molecular Tumor Board.The oncologist · 2023Article
- Data-driven support to decision-making in molecular tumour boards for lymphoma: A design science approach.Frontiers in oncology · 2022Article
- Unique genomic alterations in the circulating tumor DNA of patients with solid tumors brain metastases.Neuro-oncology advancesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Comprehensive genomic profiling to inform targeted therapy selection is a central part of oncology care. However, the volume and complexity of alterations uncovered through genomic profiling make it difficult for oncologists to choose the most appropriate therapy for their patients. Here, we present a solution to this problem, The Molecular Registry of Tumors (MRT) and our Molecular Tumor Board (MTB). PATIENTS AND
methodsMRT is an internally developed system that aggregates and normalizes genomic profiling results from multiple sources. MRT serves as the foundation for our MTB, a team that reviews genomic results for all Duke University Health System cancer patients, provides notifications for targeted therapies, matches patients to biomarker-driven trials, and monitors the molecular landscape of tumors at our institution.
resultsAmong 215 patients reviewed by our MTB over a 6-month period, we identified 176 alterations associated with therapeutic sensitivity, 15 resistance alterations, and 51 alterations with potential germline implications. Of reviewed patients, 17% were subsequently treated with a targeted therapy. For 12 molecular therapies approved during the course of this work, we identified between two and 71 patients who could qualify for treatment based on retrospective MRT data. An analysis of 14 biomarker-driven clinical trials found that MRT successfully identified 42% of patients who ultimately enrolled. Finally, an analysis of 4,130 comprehensive genomic profiles from 3,771 patients revealed that the frequency of clinically significant therapeutic alterations varied from approximately 20% to 70% depending on the tumor type and sequencing test used.
conclusionWith robust informatics tools, such as MRT, and the right MTB structure, a precision cancer medicine program can be developed, which provides great benefit to providers and patients with cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.